Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETTER-2 phase III trial of Lutathera in advanced grade 2-3 GEP-NET
NL-OMON55150Phase 3Recruiting
- Sponsor
- Advanced Accelerator Applications
- Start
- Jan 2021
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing Lutathera plus standard-dose octreotide long-acting with High-dose octreotide long-acting (2 arms). Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
lutetium Lu 177 dotatateoctreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON55150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55150.